I am using 250 million shares as a future (2018) estimate that assumes some future conversions of everything out there including certain debt...actually I am using the work of someone else who figured all that out. My main point is that BP is needed if Vascepa is to become a blockbuster drug. The potential is certainly there and management has excelled at getting a large patent portfolio together that is critically important. My estimate is a best case and much can happen that could torpedo it.